Related Experiment Video

Updated: Aug 11, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

AR Signaling and the PI3K Pathway in Prostate Cancer

Megan Crumbaker1,2, Leila Khoja3,4, Anthony M Joshua5,6,7

  • 1Kinghorn Cancer Centre, St Vincent's Hospital, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. m.crumbaker@garvan.org.au.

Cancers
|April 20, 2017
PubMed

Insights

Prostate cancer progression involves androgen receptor (AR) signaling. PI3K pathway interactions with AR may drive treatment resistance, prompting investigation into PI3K inhibitors for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Background:

  • Prostate cancer is a significant cause of male cancer mortality globally.
  • Androgen receptor (AR) signaling is central to prostate cancer development and progression.
  • Treatment resistance, even with potent drugs, remains a major challenge in advanced prostate cancer.

Purpose of the Study:

  • To elucidate the role of the PI3K pathway in prostate cancer.
  • To examine the association between PI3K and AR signaling in prostate cancer pathogenesis and evolution.
  • To review the clinical utility of targeting the PI3K pathway in prostate cancer.

Main Methods:

  • Literature review of studies on PI3K pathway signaling in prostate cancer.
  • Analysis of the interplay between AR and PI3K pathways.
  • Review of clinical trial data for PI3K inhibitors in prostate cancer.

Main Results:

  • Aberrant PI3K pathway signaling is implicated in prostate cancer.
  • The PI3K pathway interacts with AR signaling, potentially mediating treatment resistance.
  • PI3K inhibitors have shown variable success in clinical settings.

Conclusions:

  • The PI3K pathway is a critical player in prostate cancer, particularly in its resistance to therapy.
  • Understanding the AR-PI3K interaction is key to overcoming treatment resistance.
  • Further research and clinical evaluation of PI3K targeting agents are warranted for prostate cancer treatment.
Keywords:
AR signalingPI3Kcastrate resistant prostate cancerprostate cancer

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...